Analysis of the Role of IgE Proteoforms in Health and Disease

Recruiting now

Conditions studied: Anaphylaxis, Mastocytosis, X-linked Agammaglobulinaemia, Venom Allergy, Chronic Spontaneous Urticaria (CSU), Type I Allergy, Medication Allergy, Healthy Control, Hereditary Alpha-Tryptasemia

In brief

The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.

Key facts

Study ID

NCT07328178

Run by

KU Leuven

People needed

200

Starts

2025-01-01

Expected to finish

2029-01-01

Last updated by the study team

2026-01-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)
• Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)

You may not qualify if…

• Absence of informed consent
• Age < 18 years old

Where it is running

• UZ/KU Leuven — Leuven, Vlaams-Brabant, Belgium (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.